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Abstract  
            Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the 
absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 
15 years 1.  Patients with POTS complain of symptoms of tachycardia, exercise intolerance, 
lightheadedness,   extreme   fatigue,   headache   and   mental   clouding.   Patients   with   POTS 
demonstrate a heart rate increase of ≥30 bpm with prolonged standing (5-30 minutes), often have 
high levels of upright plasma norepinephrine (reflecting sympathetic nervous system activation), 
and many patients have a low blood volume.  POTS can be associated with a high degree of 
functional disability.   Therapies aimed at correcting the hypovolemia and the autonomic 
imbalance may help relieve the severity of the symptoms. This review outlines the present 
understanding of the pathophysiology, diagnosis, and management of POTS.
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Introduction
            Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the 
absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 
15 years1.   Patients with POTS complain of symptoms of tachycardia, exercise intolerance, 
lightheadedness, extreme fatigue, headache and mental clouding.  This disorder is not new2, but 
has gone by many different names over the last 150 years, including mitral valve prolapse 
syndrome, neurocirculatory asthenia, orthostatic tachycardia, and orthostatic intolerance3,4. An 
advantage of the name postural tachycardia syndrome (POTS) is that it focuses attention on the 
sympathetic activation which characterizes the disorder.   This review outlines the present 
understanding   of   the   pathophysiology,   diagnosis,   and   management   of   POTS.
Physiology of Upright Posture
            Assumption of the upright posture requires prompt physiological adaptation to gravity.  
There is an instantaneous descent of ~500 ml of blood from the thorax to the lower abdomen, 
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buttocks, and legs.  In addition, there is a 10-25% shift of plasma volume out of the vasculature 
and into the interstitial tissue5.  This shift decreases venous return to the heart, resulting in a 
transient decline in both arterial pressure and cardiac filling.  This has the effect of reducing the 
pressure on the baroreceptors, triggering a compensatory sympathetic activation that results in an 
increase in heart rate and systemic vasoconstriction (countering the initial decline in blood 
pressure).  Hence, assumption of upright posture results in a 10-20 beat per minute increase in 
heart rate, a negligible change in systolic blood pressure, and a ~5 mmHg increase in diastolic 
blood pressure.
Pathophysiology of Orthostatic Dysregulation
            Failure of the regulatory mechanism to respond properly may lead to either orthostatic 
hypotension, as is seen in autonomic failure, or orthostatic tachycardia, as is seen in POTS.  
Orthostatic hypotension is defined as a fall in pressure on standing of more than 20/10 mmHg.  
However, it is common in patients with autonomic failure for the decline to be much greater than 
this, which may result in loss of consciousness soon after standing. On the other hand, in POTS, 
blood pressure is typically maintained on standing or may even increase. Heart rate rises more 
than   30   bpm   and   symptoms   reminiscent   of   impaired   cerebral   perfusion   may   develop.
Clinical Presentation of Postural Tachycardia Syndrome (POTS)
Diagnostic Criteria & Common Clinical Features
            POTS is defined (Table 1) as the presence of symptoms of orthostatic intolerance for at 
least 6 months accompanied by a heart rate increase of at least 30 beats/min within 5-30 minutes 
of assuming an upright posture.  This should occur in the absence of orthostatic hypotension (a 
fall in blood pressure >20/10 mmHg).  The syndrome must occur in the absence of prolonged 
bed   rest,   medications   that   impair   autonomic   regulation   (such   as   vasodilators,   diuretics, 
antidepressants or anxiolytic agents), or any other chronic debilitating disorders that might cause 
tachycardia (such as dehydration, anemia or hyperthyroidism).  It is important to recognize that 
this syndrome is typically disabling.  Hence, the mere observation of orthostatic tachycardia is 
not, by itself, sufficient to make the diagnosis of POTS.
Table 1: Criteria for the Postural Tachycardia Syndrome
1.  Heart rate increase ≥30 beats per minute from supine to standing (5-30 min)
2.  Symptoms get worse with standing and better with recumbence.
3.  Symptoms lasting ≥6 months
4.  Standing plasma norepinephrine ≥600 pg/ml (≥3.5 nM)
5. Absence of other overt cause of orthostatic symptoms or tachycardia (e.g. active bleeding, 
acute dehydration, medications).
            Symptoms include mental clouding (“brain fog”), blurred or tunneled vision, shortness of 
breath, palpitation, tremulousness, chest discomfort, headache, lightheadedness and nausea.  
While pre-syncope is common in these patients, only a minority (~30%) actually pass out.  The 
chest pains are almost never due to coronary artery obstruction, but are sometimes associated 
with   electrocardiographic   changes   in   the   inferior   leads,   particularly   when   upright6.  
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            Many patients complain of significant exercise intolerance and extreme fatigue.  Even 
activities of daily living, such as bathing or housework, may greatly exacerbate symptoms with 
resultant fatigue.  This can pose significant limitations on their functional capacity.  
            The disorder primarily affects women of child-bearing age.  The female:male ratio is 4:1.  
The reason for the strong female predominance is not known, but it should be noted that 
orthostatic   tolerance   is   reduced   in   normal   healthy   females7.   Others   disorders   such   as 
autoimmune diseases and irritable bowel syndrome are seen commonly in patients with POTS, 
and also have higher prevalence in women. 
            Patients frequently report that their symptoms began following acute stressors such as 
pregnancy, major surgery, or a presumed viral illness, but in others cases, symptoms develop 
more insidiously.  About 80% of female patients report an exacerbation of symptoms in the pre-
menstrual phase of their ovulatory cycle (unpublished data).  Gazit et al. have also reported an 
association between joint hypermobility and POTS8. Many patients have bowel irregularities and 
have been co-diagnosed with irritable bowel syndrome, and some have abnormalities of 
sudomotor regulation9.
Psychological Profile in POTS
            Patients with POTS are sometimes clinically diagnosed as having anxiety disorders such 
as panic disorder.  Indeed, patients demonstrate elevated scores on the Beck Anxiety Inventory10 
(23±10 vs. 7±8; P<0.001), a commonly used instrument that quantifies the magnitude of anxiety 
symptoms11.   Unfortunately, this questionnaire includes somatic anxiety symptoms (such as 
palpitation) which can result from a hyperadrenergic state such as is seen in POTS.  When a 
newer, cognitive-based measure of anxiety (the Anxiety Sensitivity Index12) is used, there was a 
trend toward less anxiety in the patients with POTS than the general population (15±10 vs. 19±9; 
P=0.063)11.   Thus, much of the anxiety attributed to patients with POTS might be due to a 
misinterpretation of their physical symptoms.
            We did find that patients with POTS often have diminished attention and concentration 
compared to matched healthy volunteers11.  Using the Inattention score from the Connors Adult 
ADHD Rating Scale13, the patients with POTS scored significantly higher than did the normal 
control subjects. 
Physical Findings in POTS
            The most striking physical feature of POTS is the severe tachycardia that develops on 
standing from a supine position.   Blood pressure and heart rate must be measured in both 
postures and should be taken not only immediately after standing but also at 2, 5 and 10 minutes 
as occasional patients have a delayed tachycardia14.   Normal subjects commonly develop a 
transient tachycardia within the 1st minute of standing that should not be mistaken for POTS. A 
sustained heart rate increase ≥30 beats per minute is considered diagnostic of orthostatic 
tachycardia (Figure 1).  The systolic blood pressure should not fall by more than 20 mmHg, and 
in many cases it will actually increase with standing.  Recent data suggests that there may be a 
significant circadian variability in the orthostatic tachycardia seen in patients with POTS15.  In a 
cohort of 17 patients with POTS, the orthostatic tachycardia was greater in the morning than in 
the evening (38±4 bpm vs. 27±3 bpm; P<0.001), while there was no diurnal difference in the 
orthostatic change in blood pressure.  These data suggest that to optimize diagnostic sensitivity, 
postural vital signs should be performed in the morning. 
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Figure 1 – Hemodynamics with Upright Posture in POTS
     The tracings for heart rate, blood pressure, and tilt table angle are 
shown for a patient with the postural tachycardia syndrome (POTS; left) 
and for a healthy control subject (right) during a 30 minute tilt head-up 
test.  With head-up tilt, the heart rte immediately increases in POTS and 
peaks at over 170 bpm prior to the end of the tilt.  In contrast the heart rate 
of the healthy control subject rises to just over 100 bpm.  The patient with 
POTS does not experience a reduction in blood pressure during the tilt 
test.  It is largely unchanged during the test.
            Cardiac auscultation may reveal a murmur of mitral valve prolapse, but significant mitral 
regurgitation is unusual.  A striking physical feature of POTS is the dependant acrocyanosis that 
occurs in 40-50% of patients with POTS (Figure 2).  These patients experience a dark red-blue 
discoloration of their legs, which are cold to the touch.  This can extend from the feet to above 
the level of the knees.  The reasons underlying this phenomenon are not clear.  The current data 
suggest that the problem is not due to increased pooling in the venous capacitance vessels, but 
rather due to decreased blood flow in the skin16,17. 
Laboratory Abnormalities in POTS
            Some authors advocate the use head-up tilt table testing as a standardized method to 
assess an individual's response to a change in posture1.  The patient is positioned on a standard 
tilt table and following baseline measurements of blood pressure and heart rate, the patient is 
inclined to a 70-degree head-up angle.  Blood pressure and heart rate are then measured either 
continuously or at least every 12 minutes. The orthostatic tachycardia is often measured in a 
similar fashion to the standing test, with a similar threshold used to diagnose orthostatic 
tachycardia (an increase of ≥30 bpm)1.  However, the physiology in response to passive standing 
on a tilt table (with the legs still) is not the same as “active standing” where the patient must 
support their own weight and maintain their balance.  The latter requires use of the “skeletal 
muscle pump” and mimics real life, while the tilt table does not.  For this reason Streeten et al. 
use similar criteria for orthostatic tachycardia (>27 bpm), but only with active standing18.  In a 
recent study, we compared the orthostatic heart rate response of these 2 methods, and found that 
the tilt table test was associated with an increased orthostatic tachycardia in both patients with 
POTS and control subjects19. While both tests were sensitive for the diagnosis of POTS with a 30 
bpm threshold for orthostatic tachycardia, the stand test had a specificity of 79% compared to 
only 23% for the tilt table test.
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            POTS patients should have only sinus tachycardia.  An electrocardiogram should be done 
routinely to rule out the presence of an accessory bypass tract or any abnormalities of cardiac 
conduction.  A Holter monitor might prove useful to exclude a re-entrant dysrhythmia, especially 
if the patient gives a history of paroxysmal tachycardia with a sudden onset and sudden offset.  
Other tests such as echocardiograms are only required in individual cases when there is doubt 
about the structural integrity of the heart. 
Figure 2 – Acrocyanosis in POTS 
    One of the more striking physical features in the postural tachycardia syndrome (POTS) is the 
gross change in dependent skin color that can occur with standing.  The panel shows the legs of 2 
people who have been standing for 5 minutes, a healthy control subject (left) and a patient with 
POTS (right).   The patient with POTS (right) has significant dark red mottling of her legs 
extending up to the knees while standing, while the control subject does not have a similar 
discoloration.  
            We often measure plasma norepinephrine levels in both a supine and standing position (at 
least 15 minutes in each position prior to blood sampling).  The supine norepinephrine is often 
high normal in patients with POTS, while the upright norepinephrine is usually elevated (>600 
pg/ml), a reflection of the exaggerated neural sympathetic tone that is present in these patients 
while upright. 
               Tests of autonomic nervous system function typically show intact or exaggerated 
autonomic reflex responses.  These patients often have preserved vagal function as reflected by 
their sinus arrhythmia ratio in response to deep breathing.  They often have a vigorous pressor 
response to the Valsalva maneuver, with an exaggerated blood pressure recovery and overshoot 
both before and after release20.
            The blood volume is low in many patients with POTS5.  This can be objectively assessed 
with nuclear medicine tests to directly measure either the plasma volume or the red cell volume.  
This knowledge may help to focus the treatment plan.
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            Some patients with POTS have co-existent complaints of episodic flushing.  In about half 
of these cases there is an associated mast cell activation disorder20.  This can be diagnosed by 
collecting   urine   from   individual   2-4   hour   voids   following   a   severe   flushing   spell   for 
determination of methylhistamines. 
Differential Diagnosis
            The clinical picture of POTS can be confused with pheochromocytoma because of the 
paroxysms of hyperadrenergic symptoms.  Patients with pheochromocytoma are more likely to 
have symptoms while lying down than POTS patients, and often have much higher plasma 
norepinephrine levels.  The diagnosis of pheochromocytoma is made by assessment of plasma or 
urinary metanephrines21. 
            There is commonly some confusion between neurally mediated syncope and POTS.  
There is a clinical overlap between the 2 disorders, such that about 30% of patients with POTS 
also have neurally mediated syncope. Nonetheless, most patients with POTS do not faint.  
            Almost all patients with POTS also have associated fatigue.  The reasons are not entirely 
clear.  In some patients, but not all, the fatigue improves with pharmacological control of the 
orthostatic tachycardia.   Some patients with POTS have symptomatic overlap with chronic 
fatigue syndrome.
Pathophysiology of POTS
               Tachycardia   and   asthenia   on   standing   is   a   final   common   pathway   of   many 
pathophysiological processes. POTS is therefore best viewed as a syndrome rather than a 
disease. Many disorders with a common key clinical presentation (the orthostatic tachycardia) 
have been described.  Over the last decade, much has been learned about specific forms or sub-
types within POTS, although a simple test to categorize the individual patient remains elusive.  
We discuss here the common POTS phenotypes including neuropathic POTS and central 
hyperadrenergic POTS (Figure 3).
     There are multiple distinct pathophysiological subtypes within the postural tachycardia 
syndrome (POTS).   The  top panel  (3a) shows a basal situation with a normal amount of 
sympathetic nervous system outflow from the brain that activates receptors in the blood vessels 
(vascular tone & venous return), heart (heart rate & contractility) and kidney (blood volume 
regulation through renin).  Panel 3b shows a schematic of Neuropathic POTS.  There is patchy 
denervation of the sympathetic innervation of the blood vessels in the extremities (especially the 
legs) and the kidney with subsequent hypovolemia and increased orthostatic venous pooling.  
This feeds back to the brain to increase sympathetic nervous system outflow in a compensatory 
effort.   This increased sympathoneural flow is sensed most in the heart where there is no 
denervation.  Panel 3c shows a schematic of Central Hyperadrenergic POTS.  In this case, the 
underlying problem is excessive sympathetic nervous outflow from the brain that affects the 
blood vessels, kidneys and the heart.  In addition to tachycardia, this form of POTS is often 
associated with orthostatic hypertension.
Neuropathic POTS
            Considering that POTS patients have high plasma NE levels, it would seem paradoxical 
that a neuropathy is proposed as an underlying process.  Yet some of them have a form of 
dysautonomia, with preferential denervation of sympathetic nerves innvervating the lower 
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limbs22-24.   There have been several findings consistent with this hypothesis.   The results of 
sudomotor axon reflex testing22  and galvanic skin stimulation23  support this as well as skin 
biopsy results25.  Further, these patients have been found to be hypersensitive to infusions of 
norepinephrine and phenylephrine into veins of the foot, despite high circulating plasma 
norepinephrine concentrations24.  This suggests that there is a denervation hypersensitivity of the 
leg veins.  Using a segmental norepinephrine spillover approach, Jacob et al.26 demonstrated that 
patients with POTS had normal sympathetic neuronal norepinephrine release in their arms, but 
less norepinephrine release (and thus less sympathetic activation) in their lower body.
Figure 3 – Pathophysiological Schema in POTS
Hypovolemia & Blood Volume Regulation
            Many patients with POTS have low plasma volumes27,28, but not all29.  To determine if 
hypovolemia existed in an unselected group of POTS patients, we studied 15 patients with POTS 
(not selected for blood volume) and 14 control subjects5.  Plasma volume was measured using 
131-I labeled human serum albumin using a dye dilution technique, and compared to the predicted 
blood volume for each individual, based upon their height, weight, and gender.  As can be seen 
in Figure 4, the control subjects did not have a significant plasma volume deficit (0.8±2.5%).  In 
contrast, the patients with POTS had a plasma volume deficit of 12.8±2.0% (P<0.001).  
               The renin-angiotensin-aldosterone system plays a key role in the neurohormonal 
regulation of plasma volume in humans.   Plasma renin activity and angiotensin II would be 
expected to increase in response to hypovolemia in order to promote blood volume expansion.  
Angiotensin II promotes sodium and water retention directly by stimulating sodium resorption in 
the proximal tubules, and indirectly by stimulating aldosterone secretion.
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Figure 4 – Blood Volume Deviation in POTS
The 3 panels show the blood volumes of control subjects and patients with POTS 
compared to hat expected based on their individual height, weight and gender.  
Data are shown for plasma volume (PV; Panel A), red cell volume (RC; Panel 
B) and total blood volume (TBV; Panel C).  The plasma volume and total blood 
volume of the control subjects was similar to their expected values. The patients 
with POT had a deficit of their plasma volume (Panel A), red cell volume (Panel 
B) and total blood volume (Panel C) compared to the control group.  Figures 
adapted with data from Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape 
SY, Byrne D, Robertson D.  The Renin-Aldosterone Paradox and Perturbed Blood 
Volume Regulation Underlying the Postural Tachycardia Syndrome.  Circulation 
2005; 111:1574-1582.
            Patients with orthostatic tachycardia who were also hypovolemic have low levels of 
standing plasma renin activity and aldosterone compared to normovolemic patients21,2.  This is 
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true in both supine (190±140 pM vs. 380±230 pM; P=0.017) and upright posture (480±290 pM 
vs. 810±370 pM; P=0.019).  One would have expected a compensatory increase in both plasma 
renin activity and aldosterone given the hypovolemia in these patients. This low level of plasma 
renin activity and aldosterone is a paradox that remains unexplained.  These data suggest that 
abnormalities in the renin-angiotensin-aldosterone axis might have a role in the pathophysiology 
of POTS by contributing to hypovolemia and impaired sodium retention. Such hypovolemia 
could be accounted for by a neuropathic process involving the kidney.  A significant modulator 
of renin release is the sympathetic nervous system. Thus perturbations in the renin-aldosterone 
system   might   result   from   partial   sympathetic   denervation   involving   the   kidney.
Central Hyperadrenergic POTS
            As a part of the definition, POTS is associated with a hyperadrenergic state (Table 1).  In 
many   such   cases,   the   hyperadrenergic   state   is   secondary   to   a   partial   dysautonomia   or 
hypovolemia.  There are some cases, however, in which the primary underlying problem seems 
to be excessive sympathetic discharge.   These patients often have extremely high levels of 
upright norepinephrine.  While we require the upright norepinephrine level to be >600 pg/ml for 
the diagnosis of POTS, the hyperadrenergic subgroup often has upright norepinephrine level 
>1000 pg/ml and it is occasionally >2000 pg/ml.  These patients sometimes have large increases 
in blood pressure on standing, indicating that baroreflex buffering is somehow impaired.  
               Central hyperadrenergic POTS in its most florid form is much less common than 
neuropathic POTS, comprising only ~10% of patients.   Thus therapy in these cases usually 
targets a decrease in sympathetic tone both centrally and peripherally.  
            Central sympatholytics such as methyldopa or clonidine can be used.  Peripheral beta-
adrenergic blockade may be better tolerated by these patients than by those with neuropathic 
POTS.
Norepinephrine Transporter Deficiency
            A specific genetic abnormality has been identified in a kindred with hyperadrenergic 
POTS30.   These individuals have a single point mutation in the norepinephrine transporter 
(NET).  The resultant inability to adequately clear norepinephrine produces a state of excessive 
sympathetic activation in response to a variety of sympathetic stimuli. While rare, this mutation 
has taught us much about the importance of a functional NET.
               Although functional NET mutations might be infrequent, pharmacological NET 
inhibition is very common.  Many antidepressant and attention deficit medications work at least 
in   part   through   inhibition   of   NET.   This   includes   traditional   drugs   such   as   tricyclic 
antidepressants, and newer medications which are pure NET inhibitors (e.g. atomoxetine or 
reboxetine).    Both we31  and others32  have found that pharmacological NET inhibition can 
recreate   an   orthostatic   tachycardia   phenotype   in   susceptible   healthy   volunteer   subjects.  
Yohimbine, a central alpha-2 antagonist that will also increase synaptic norepinephrine, can also 
cause orthostatic tachycardia33.
Mast Cell Activation
            Some patients with POTS have co-existent mast cell activation. These patients have 
episodic  flushing and abnormal  increases in  urine  methylhistamine (the primary  urinary 
metabolite of histamine)20.  Methylhistamine should ideally be measured in 2 hour aliquots at the 
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time of a flushing episode and not just in a random 24 hour period.  Other associated symptoms 
include shortness of breath, headache, lightheadedness, excessive diuresis, and gastrointestinal 
symptoms such as diarrhea, nausea, and vomiting.   Flushing can be triggered by long-term 
standing, exercise, premenstrual cycle, meals, and sexual intercourse.  These patients often have 
a hyperadrenergic response to posture, with both orthostatic tachycardia and hypertension.  They 
demonstrate a vigorous sympathetic vasopressor response during the Valsalva maneuver with a 
blood pressure overshoot in late phase II and an exaggerated phase IV blood pressure overshoot. 
It is not clear if mast cell activation, releasing vasoactive mediators, represents the primary event 
in these patients or if sympathetic activation, through release of norepinephrine, neuropeptide Y 
and ATP, is the cause of mast cell activation34. 
            In these patients, beta-adrenergic antagonists can actually trigger an episode and worsen 
symptoms.  Centrally acting agents to decrease the sympathetic nervous system discharge (e.g. 
methyldopa or clonidine) may prove effective.  Alternatively, treatment could target mast cell 
mediators with a combination of antihistamines (H1- and H2-antagonists) and with the cautious 
use of non-steroidal agents (high dose aspirin) in refractory cases.  
Non-Pharmacological Treatment of POTS
             No therapy is successful for all patients with POTS. Initial efforts should focus on 
identifying and treating any reversible causes.  Potentially contributory medications (especially 
vasodilators, diuretics, and drugs that inhibit NET) should be withdrawn.  If a patient has been 
through   prolonged   bedrest,   their   symptoms   will   gradually   improve   as   they   recondition 
themselves to upright posture.  Treatment should be optimized for any chronic disease that is 
present.  If there is clear evidence of a re-entrant supraventricular arrhythmia, then this should be 
treated, including with radiofrequency ablation as appropriate.  However, radiofrequency sinus 
node modification for the sinus tachycardia of POTS is not recommended.  This often makes the 
patient’s symptoms worse (and occasionally the patient becomes pacemaker dependent). Specific 
therapies are summarized in Table 2.
            It is important to educate the patient about the nature of the disorder.  The patient should 
avoid aggravating factors such as dehydration, and extreme heat.  In order to ensure adequate 
hydration, we ask our patients to consume 8-10 cups of water daily and to rapidly drink 16 fl oz 
of water to lower their heart rates35.  In addition, they are asked to aggressively increase their 
sodium intake up to 200 mEq/day.  This is often hard to achieve without NaCl tablets 1 gm/tablet 
TID with meals.  Elastic support hose can help to minimize the degree of peripheral venous 
pooling and enhance venous return.  We recommend 30-40 mmHg of counter-pressure and they 
should come up to the waist.  If the stockings are only knee-high, a line of edema can form just 
above the stockings.  Their use can be limited by their tolerability as the stockings can be hot, 
itchy and uncomfortable.  Exercise (both aerobic and resistance training) is also encouraged and 
has been  shown to be  beneficial36.   In  addition  to  reversing any  “deconditioning”,  this 
intervention can also increase blood volume.  Vigorous exercise may acutely worsen symptoms 
and may even result in prolonged fatigue.  It is important that patients start slowly and remain 
within range of their “target heart rate” in the early stages to avoid symptoms that might 
discourage further exercise.
             Acute blood volume expansion is effective at controlling the heart rate and acutely 
improving   symptoms.   Jacob   et   al.37  found   that   1   liter   of   physiological   saline   infused 
intravenously over 1 hour decreased the orthostatic tachycardia from 33±5 bpm before the 
infusion to 15±3 bpm immediately following the infusion.  The physiological saline was more 
effective at heart rate control than were treatments with either an alpha-1 agonist or an alpha-2 
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agonist.  This treatment is not practical on a day to day basis as a medical setting is required to 
insert the intravenous catheter and infuse the saline.   Recently, there have been reports of 
patients having regular saline infusions, typically 1 liter of normal saline every other day or 
every day.  Many report an improvement in symptoms.  However, there are not yet objective 
data to substantiate such benefit.  Further, there is a risk of vascular access complications or 
infection.  At this time, such therapy for patients with POTS should be considered cautiously.
Pharmacological Treatment of POTS
            No medicines are approved by the United States Food and Drug Administration for the 
treatment of POTS.  Thus all agents are used for this disorder are “off label”.  Furthermore, there 
are  no   pharmacological   agents   that   have  been  tested   in  a   long-term   properly  powered 
randomized clinical trial.  
Table 2: Treatments for the Postural Tachycardia Syndrome
2A
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2B
NaCl – Table salt; PO – by mouth; OD – once daily; BID – 
twice daily; TID – three times daily; QID – four times 
daily; IV – intravenous; 
            In patients in whom the presence of hypovolemia is either known or strongly suspected, 
fludrocortisone (an aldosterone analogue) is often used.  Through enhanced sodium retention, it 
should expand the plasma volume, although there is a paucity of data regarding the exact 
mechanisms of action.  Although fairly well tolerated, side effects can include hypokalemia, 
hypomagnesemia, worsening headaches, acne, and fluid retention with edema.  Another volume 
expanding agent that may be helpful for short-term use is oral vasopressin (DDAVP).  This agent 
causes   the  kidney  to  retain   free   water,   but   not   sodium.   Potential  side   effects   include 
hyponatremia, edema and headache. Erythropoietin has occasionally proven useful in patients 
with POTS who are refractory to other forms of therapy.  While the primary mode of action is 
likely an increase in intravascular volume via its increase in red cell mass, erythropoietin also 
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appears to have a direct vasoconstrictive effect, possibly through enhanced red cell mediated 
nitric oxide scavenging38.   Treatment with erythropoietin has many drawbacks including the 
significant expense and the need for subcutaneous administration. 
            Central sympatholytic medications are often useful and well tolerated in patients with the 
central hyperadrenergic form of POTS, but may not be as well tolerated in neuropathic POTS.  
Clonidine is an alpha 2 agonist that acts centrally to decrease sympathetic nervous system tone.  
Clonidine, at doses of 0.05 mg to 0.2 mg PO BID, can stabilize heart rate and blood pressure in 
patients with a large amount of postganglionic sympathetic involvement.  Unfortunately, it can 
also cause drowsiness, fatigue and worsen the mental clouding of some patients.  Methyldopa, a 
false neurotransmitter, is sometimes more successful in controlling symptoms in these patients at 
doses of 125 mg to 250 mg PO TID39.  
            When used in low doses, beta-adrenergic antagonists can be useful.  We typical use 
propranolol 10-20 mg PO BID-QID.  While this dose range is small, such doses can often have a 
significant impact on heart rate control, and higher doses are often not tolerated due to 
hypotension and fatigue.
            Since a failure of vascular resistance may be an integral part of neuropathic POTS, 
vasoconstrictors such as midodrine (an alpha-1 agonist) can be employed40.   Some patients 
cannot tolerate this agent due to the unpleasant sensation of scalp tingling or goosebumps.  
Midodrine can also cause hypertension.
            We recently reported that an unselected group of patients seen in our inpatient research 
unit were given a trial of the acetylcholinesterase inhibitor pyridostigmine.  By increasing the 
levels of synaptic acetylcholine at both the autonomic ganglia and the peripheral muscarinic 
parasympathetic receptors, pyridostigmine significantly restrained the heart rate in response to 
standing in our patients with POTS.  We prescribe pyridostigmine 30mg to 60 mg PO TID alone 
or in combination with low dose propranolol.  Pyridostigmine can enhance bowel motility, so it 
is not always well tolerated in patients with diarrhea-predominant irritable bowel syndrome 
symptoms.  
            While most of the treatments discussed above have focused on the control of heart rate, 
many patients are also greatly troubled by mental clouding.   Modafinil, a stimulant whose 
mechanism is not yet clear, has been used in some patients with resulting improvement in 
alertness.   However, caution is advised as it may aggravate the orthostatic tachycardia41.  
Conclusions
            POTS is a disorder of the autonomic nervous system in which many symptoms can be 
treated.  The cardinal manifestation is symptomatic orthostatic tachycardia. The disorder can 
produce substantial disability among otherwise healthy people.  Patients with POTS demonstrate 
a heart rate increase of ≥30 bpm with prolonged standing (5-30 minutes), often have high levels 
of upright plasma norepinephrine, and many patients have a low blood volume.  Therapies aimed 
at correcting the hypovolemia and the autonomic imbalance may help relieve the severity of the 
symptoms.  Continued research is vital to better understand this disorder and to differentiate its 
various subtypes.
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